Eerdekens M - Search Results

1

An open-label extension trial of risperidone monotherapy in the treatment of bipolar I disorder.

Hirschfeld RM, Eerdekens M, Kalali AH, Canuso CM, Khan AA, Karcher K, Palumbo JM. Hirschfeld RM, et al. Among authors: eerdekens m. Int Clin Psychopharmacol. 2006 Jan;21(1):11-20. doi: 10.1097/01.yic.0000177017.41558.fc. Int Clin Psychopharmacol. 2006. PMID: 16317312 Clinical Trial.

2

Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial.

Hirschfeld RM, Keck PE Jr, Kramer M, Karcher K, Canuso C, Eerdekens M, Grossman F. Hirschfeld RM, et al. Among authors: eerdekens m. Am J Psychiatry. 2004 Jun;161(6):1057-65. doi: 10.1176/appi.ajp.161.6.1057. Am J Psychiatry. 2004. PMID: 15169694 Clinical Trial.

3

Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic.

Fleischhacker WW, Eerdekens M, Karcher K, Remington G, Llorca PM, Chrzanowski W, Martin S, Gefvert O. Fleischhacker WW, et al. Among authors: eerdekens m. J Clin Psychiatry. 2003 Oct;64(10):1250-7. doi: 10.4088/jcp.v64n1017. J Clin Psychiatry. 2003. PMID: 14658976 Clinical Trial.

4

Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol.

Smulevich AB, Khanna S, Eerdekens M, Karcher K, Kramer M, Grossman F. Smulevich AB, et al. Among authors: eerdekens m. Eur Neuropsychopharmacol. 2005 Jan;15(1):75-84. doi: 10.1016/j.euroneuro.2004.06.003. Eur Neuropsychopharmacol. 2005. PMID: 15572276 Clinical Trial.

5

A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia.

Luthringer R, Staner L, Noel N, Muzet M, Gassmann-Mayer C, Talluri K, Cleton A, Eerdekens M, Battisti WP, Palumbo JM. Luthringer R, et al. Among authors: eerdekens m. Int Clin Psychopharmacol. 2007 Sep;22(5):299-308. doi: 10.1097/YIC.0b013e3281c55f4f. Int Clin Psychopharmacol. 2007. PMID: 17690599 Clinical Trial.

6

Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies.

Emsley R, Berwaerts J, Eerdekens M, Kramer M, Lane R, Lim P, Hough D, Palumbo J. Emsley R, et al. Among authors: eerdekens m. Int Clin Psychopharmacol. 2008 Nov;23(6):343-56. doi: 10.1097/YIC.0b013e328314e1f3. Int Clin Psychopharmacol. 2008. PMID: 18854723

7

Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic.

Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Kane JM, et al. Among authors: eerdekens m. Am J Psychiatry. 2003 Jun;160(6):1125-32. doi: 10.1176/appi.ajp.160.6.1125. Am J Psychiatry. 2003. PMID: 12777271 Clinical Trial.

8

One-year open-label safety and efficacy study of paliperidone extended-release tablets in patients with schizophrenia.

Kramer M, Simpson G, Maciulis V, Kushner S, Liu Y, Lim P, Hough D, Palumbo J, Eerdekens M. Kramer M, et al. Among authors: eerdekens m. CNS Spectr. 2010 Aug;15(8):506-14. doi: 10.1017/s1092852900000456. CNS Spectr. 2010. PMID: 20703197 Clinical Trial.

9

Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder.

Lindenmayer JP, Khan A, Eerdekens M, Van Hove I, Kushner S. Lindenmayer JP, et al. Among authors: eerdekens m. Eur Neuropsychopharmacol. 2007 Jan 15;17(2):138-44. doi: 10.1016/j.euroneuro.2006.08.004. Epub 2006 Oct 17. Eur Neuropsychopharmacol. 2007. PMID: 17049818 Clinical Trial.

Subjects were patients with schizophrenia or schizoaffective disorder enrolled in extension studies (Study A and Study B) after participating in 12-week studies of long-acting injectable risperidone [Kane, J.M., Eerdekens, M., Lindenmayer, J.-P., Keith, S.J., …

Subjects were patients with schizophrenia or schizoaffective disorder enrolled in extension studies (Study A and Study B) after participatin …

10

To what extent do the PANSS and CGI-S overlap?

Rabinowitz J, Mehnert A, Eerdekens M. Rabinowitz J, et al. Among authors: eerdekens m. J Clin Psychopharmacol. 2006 Jun;26(3):303-7. doi: 10.1097/01.jcp.0000218407.10362.6e. J Clin Psychopharmacol. 2006. PMID: 16702895

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

117 results

Search Page